Human trials are starting for a new drug that promises to reverse the damage caused by Huntington’s disease, reports International Business Times (Australia).
The drug passed clinical trials on mice and monkeys.
Brian Leavitt, a Canada neurology expert from UBC, is leading the human trial.
